Inhibition of glycogen synthase kinase-3 increases the cytotoxicity of enzastaurin

Journal of Investigative Dermatology

Volumn 131, Issue 7, 2011, Pages 1442-1449

  Rovedo, Mark A ^a   Krett, Nancy L ^a   Rosen, Steven T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AR A 014418; BETA CATENIN; CYCLIN D1; ENZASTAURIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; HERMES ANTIGEN; LUCIFERASE; MESSENGER RNA; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DRUG CYTOTOXICITY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; ONCOGENE C MYC; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPREGULATION;

EID: 79958776304     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2011.70     Document Type: Article

References (44)

1. Bates RC, Edwards NS, Burns GF et al. (2001) A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/ Akt in colon carcinoma cells. Cancer Res 61:5275-83 (Pubitemid 32681564)
2. Bellei B, Cota C, Amantea A et al. (2006) Association of p53 Arg72Pro polymorphism and beta-catenin accumulation in mycosis fungoides. Br J Dermatol 155:1223-9 (Pubitemid 44729999)
3. Bellei B, Pacchiarotti A, Perez M et al. (2004) Frequent beta-catenin overexpression without exon 3 mutation in cutaneous lymphomas. Mod Pathol 17:1275-81 (Pubitemid 39312954)
4. Billin AN, Thirlwell H, Ayer DE (2000) Beta-catenin-histone deacetylase interactions regulate the transition of LEF1 from a transcriptional repressor to an activator. Mol Cell Biol 20:6882-90
5. Bourguignon LY, Gilad E, Brightman A et al. (2006) Hyaluronan-CD44 interaction with leukemia-associated RhoGEF and epidermal growth factor receptor promotes Rho/Ras co-activation, phospholipase C epsilon-Ca2+ signaling, and cytoskeleton modification in head and neck squamous cell carcinoma cells. J Biol Chem 281:14026-40 (Pubitemid 43848329)
6. Bourguignon LY, Gilad E, Rothman K et al. (2005) Hyaluronan-CD44 interaction with IQGAP1 promotes Cdc42 and ERK signaling, leading to actin binding, Elk-1/estrogen receptor transcriptional activation, and ovarian cancer progression. J Biol Chem 280:11961-72 (Pubitemid 40418513)
7. Chen RH, Ding WV, McCormick F (2000) Wnt signaling to beta-catenin involves two interactive components. Glycogen synthase kinase-3beta inhibition and activation of protein kinase C. J Biol Chem 275:17894-9 (Pubitemid 30430843)
8. Clevers H, van de Wetering M (1997) TCF/LEF factor earn their wings. Trends Genet 13:485-9 (Pubitemid 28004922)
9. Cohen P, Goedert M (2004) GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 3:479-87 (Pubitemid 38807530)
10. Daniels DL, Weis WI (2002) ICAT inhibits beta-catenin binding to Tcf/Lef-family transcription factors and the general coactivator p300 using independent structural modules. Mol Cell 10:573-84 (Pubitemid 35291069)
11. Deng J, Miller SA, Wang HY et al. (2002) Beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. Cancer Cell 2:323-34 (Pubitemid 41043966)
12. Deng J, Xia W, Miller SA et al. (2004) Crossregulation of NF-kappaB by the APC/GSK-3beta/beta-catenin pathway. Mol Carcinog 39:139-46
13. Eastman Q, Grosschedl R (1999) Regulation of LEF-1/TCF transcription factors by Wnt and other signals. Curr Opin Cell Biol 11:233-40 (Pubitemid 29164039)
14. Fanning A, Volkov Y, Freeley M et al. (2005) CD44 cross-linking induces protein kinase C-regulated migration of human T lymphocytes. Int Immunol 17:449-58 (Pubitemid 40568120)
15. Fichter M, Hinrichs R, Eissner G et al. (1997) Expression of CD44 isoforms in neuroblastoma cells is regulated by PI 3-kinase and protein kinase C. Oncogene 14:2817-24 (Pubitemid 27313414)
16. Godar S, Ince TA, Bell GW et al. (2008) Growth-inhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression. Cell 134:62-73 (Pubitemid 351905743)
17. Goncalves V, Matos P, Jordan P (2008) The beta-catenin/TCF4 pathway modifies alternative splicing through modulation of SRp20 expression. RNA 14:2538-49
18. Gould TD, Einat H, Bhat R et al. (2004) AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol 7:387-90 (Pubitemid 39648068)
19. Graff JR, McNulty AM, Hanna KR et al. (2005) The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65:7462-9 (Pubitemid 41161281)
20. Gumbiner BM (1995) Signal transduction of beta-catenin. Curr Opin Cell Biol 7:634-40
21. Gwak J, Cho M, Gong SJ et al. (2006) Protein-kinase-C-mediated beta-catenin phosphorylation negatively regulates the Wnt/beta-catenin pathway. J Cell Sci 119:4702-9 (Pubitemid 44964266)
22. He TC, Sparks AB, Rago C et al. (1998) Identification of c-MYC as a target of the APC pathway. Science 281:1509-12 (Pubitemid 28425575)
23. Hecht A, Vleminckx K, Stemmler MP et al. (2000) The p300/CBP acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates. EMBO J 19:1839-50 (Pubitemid 30204395)
24. Hoogeboom D, Essers MA, Polderman PE et al. (2008) Interaction of FOXO with beta-catenin inhibits beta-catenin/T cell factor activity. J Biol Chem 283:9224-30
25. Huber O, Korn R, McLaughlin J et al. (1996) Nuclear localization of beta-catenin by interaction with transcription factor LEF-1. Mech Dev 59:3-10 (Pubitemid 26325455)
26. Jakob T, Neuber K, Altenhoff J et al. (1996) Stage-dependent expression of CD7, CD45RO, CD45RA and CD25 on CD4-positive peripheral blood T-lymphocytes in cutaneous T-cell lymphoma. Acta Derm Venereol 76:34-6 (Pubitemid 26090867)
27. Kothapalli D, Flowers J, Xu T et al. (2008) Differential activation of ERK and Rac mediates the proliferative and anti-proliferative effects of hyaluronan and CD44. J Biol Chem 283:31823-9
28. Lin YH, Yang-Yen HF (2001) The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem 276:46024-30
29. Mann B, Gelos M, Siedow A et al. (1999) Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci USA 96:1603-8 (Pubitemid 29098498)
30. Martins DF, Rosa AO, Gadotti VM et al. (2011) The antinociceptive effects of AR-A014418, a selective inhibitor of glycogen synthase kinase-3 beta, in mice. J Pain 3:315-22
31. Medina M, Avila J (2010) Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease. Curr Pharm Des 16:2790-8
32. Ogbomo H, Biru T, Michaelis M et al. (2011) The anti-tumoral drug enzastaurin inhibits natural killer cell cytotoxicity via activation of glycogen synthase kinase-3beta. Biochem Pharmacol 81:251-8
33. Orteu CH, Li W, Allen MH et al. (1997) CD44 variant expression in cutaneous T-cell lymphoma. J Cutan Pathol 24:342-9 (Pubitemid 27312014)
34. Ougolkov AV, Bone ND, Fernandez-Zapico ME et al. (2007) Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood 110:735-42 (Pubitemid 47105412)
35. Ougolkov AV, Fernandez-Zapico ME, Savoy DN et al. (2005) Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 65:2076-81 (Pubitemid 40490111)
36. Querfeld C, Kuzel TM, Kim YH et al. Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma. Leuk Lymphoma (in press)
37. Querfeld C, Rizvi MA, Kuzel TM et al. (2006) The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol 126:1641-7
38. Raab MS, Breitkreutz I, Tonon G et al. (2009) Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling. Blood 113:1513-21
39. Rook AH, Gottlieb SL, Wolfe JT et al. (1997) Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis. Clin Exp Immunol 107(Suppl 1):16-20
40. Tago K, Nakamura T, Nishita M et al. (2000) Inhibition of Wnt signaling by ICAT, a novel beta-catenin-interacting protein. Genes Dev 14:1741-9 (Pubitemid 30602993)
41. Takemaru KI, Moon RT (2000) The transcriptional coactivator CBP interacts with beta-catenin to activate gene expression. J Cell Biol 149:249-54 (Pubitemid 30227143)
42. Voutilainen KA, Anttila MA, Sillanpaa SM et al. (2006) Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer. J Clin Pathol 59:460-7
43. Wielenga VJ, Smits R, Korinek V et al. (1999) Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol 154:515-23 (Pubitemid 29094101)
44. Xu Y, Stamenkovic I, Yu Q (2010) CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res 70:2455-64